Sarepta Therapeutics | SRPT - Cash And Equivalent


Sarepta Therapeutics reported $464.45M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Daiichi Sankyo JPY 449.81B 92.35B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Insmed USD 582.19M 71.74M Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novavax USD 228.36M 12.27M Mar/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026